← Leaderboards
Gil Y Melmed
Cedars-Sinai Medical Center
$1,256,705
Attributed
$2,513,409
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $691.5K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,513,409 · 1
By mechanism
R01$2,513,409 · 1
Top collaborators
- David M. Underhill4 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Stephen L. Shiao$2,835,837
- Magali Noval Rivas$6,076,549
- Dermot Patrick McGovern$11,374,898
- Marla C Dubinsky$1,620,360
Others in their field
Other Emerging Leaders on “Disorder Risk”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy M Willson · University Of Cape Town$32,741,597
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
Disorder RiskAntibody FormationAllelesDisease ModelAntifungal TherapyBacteriaBehaviorBiopsyDesignBloodBlood SpecimenCaringCell PhysiologyChemistryChronicClinical DataClinical RemissionClinical TrialsColitisAffectColonoscopyConventional TherapyCrohn&AposDouble-Blind Method
Grant awards (4)
Targeting the Mycobiome in Genetically Defined Patients with Crohns Disease$548,343
R01 · FY2025 · DK
Targeting the Mycobiome in Genetically Defined Patients with Crohns Disease$633,061
R01 · FY2023 · DK
Targeting the Mycobiome in Genetically Defined Patients with Crohns Disease$640,531
R01 · FY2022 · DK
Targeting the Mycobiome in Genetically Defined Patients with Crohns Disease$691,474
R01 · FY2021 · DK